MX2019014482A - Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. - Google Patents
Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación.Info
- Publication number
- MX2019014482A MX2019014482A MX2019014482A MX2019014482A MX2019014482A MX 2019014482 A MX2019014482 A MX 2019014482A MX 2019014482 A MX2019014482 A MX 2019014482A MX 2019014482 A MX2019014482 A MX 2019014482A MX 2019014482 A MX2019014482 A MX 2019014482A
- Authority
- MX
- Mexico
- Prior art keywords
- gonadotropin
- releasing hormone
- blood loss
- menstrual blood
- uterine fibroids
- Prior art date
Links
- 206010046798 Uterine leiomyoma Diseases 0.000 title abstract 2
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 201000010260 leiomyoma Diseases 0.000 title abstract 2
- 230000002175 menstrual effect Effects 0.000 title abstract 2
- 239000002474 gonadorelin antagonist Substances 0.000 title 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- -1 3-[2-fluoro-5-(2 Chemical class 0.000 abstract 1
- 239000004381 Choline salt Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 235000019417 choline salt Nutrition 0.000 abstract 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- KQWHKLZRDFJOCN-UHFFFAOYSA-N thieno[3,4-d]pyrimidine Chemical class N1=CN=CC2=CSC=C21 KQWHKLZRDFJOCN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515232P | 2017-06-05 | 2017-06-05 | |
| PCT/EP2018/064767 WO2018224497A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014482A true MX2019014482A (es) | 2020-08-17 |
Family
ID=62636157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014482A MX2019014482A (es) | 2017-06-05 | 2018-06-05 | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. |
| MX2023013582A MX2023013582A (es) | 2017-06-05 | 2018-06-05 | Regimenes de dosificacion de antagonista de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruacion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013582A MX2023013582A (es) | 2017-06-05 | 2018-06-05 | Regimenes de dosificacion de antagonista de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruacion. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11759464B2 (enExample) |
| EP (2) | EP4509173A3 (enExample) |
| JP (2) | JP7292566B2 (enExample) |
| KR (1) | KR102884301B1 (enExample) |
| CN (1) | CN110996957A (enExample) |
| AU (2) | AU2018280741B2 (enExample) |
| CA (1) | CA3066188A1 (enExample) |
| DK (1) | DK3634419T3 (enExample) |
| EA (1) | EA201992812A1 (enExample) |
| ES (1) | ES3018358T3 (enExample) |
| FI (1) | FI3634419T3 (enExample) |
| HR (1) | HRP20250390T1 (enExample) |
| HU (1) | HUE070907T2 (enExample) |
| MX (2) | MX2019014482A (enExample) |
| PL (1) | PL3634419T3 (enExample) |
| PT (1) | PT3634419T (enExample) |
| SG (1) | SG11201911599XA (enExample) |
| WO (1) | WO2018224497A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| JP2021532160A (ja) * | 2018-08-01 | 2021-11-25 | アッヴィ・インコーポレイテッド | エラゴリックスに関する投与計画 |
| WO2020089190A2 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| KR20210100623A (ko) * | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
| US20220288154A1 (en) * | 2019-08-08 | 2022-09-15 | ObsEva S.A. | Gnrh antagonists for the treatment of estrogen-dependent disorders |
| KR20220061120A (ko) * | 2019-08-08 | 2022-05-12 | 옵스에파 에스에이 | 에스트로겐-의존성 장애 치료용 조성물 및 방법 |
| KR20210155350A (ko) | 2020-06-15 | 2021-12-22 | 한상왕 | 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| KR102738115B1 (ko) | 2024-03-25 | 2024-12-05 | 한상왕 | 자궁근종 예방, 개선 또는 치료용 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| PT1939204E (pt) * | 2005-10-19 | 2013-03-14 | Kissei Pharmaceutical | Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal |
| EP2535342B1 (en) * | 2010-02-10 | 2014-08-06 | Kissei Pharmaceutical Co., Ltd. | Salt of fused heterocyclic derivative and crystal thereof |
| JP6268093B2 (ja) | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| AU2017309015B2 (en) | 2016-08-08 | 2022-09-15 | Kissei Pharmaceutical Co., Ltd. | Administration and dosage of therapeutic agent for endometriosis |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| KR20210100623A (ko) | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
-
2018
- 2018-06-05 US US16/619,702 patent/US11759464B2/en active Active
- 2018-06-05 MX MX2019014482A patent/MX2019014482A/es unknown
- 2018-06-05 PT PT187319769T patent/PT3634419T/pt unknown
- 2018-06-05 EP EP24221894.9A patent/EP4509173A3/en active Pending
- 2018-06-05 EA EA201992812A patent/EA201992812A1/ru unknown
- 2018-06-05 PL PL18731976.9T patent/PL3634419T3/pl unknown
- 2018-06-05 ES ES18731976T patent/ES3018358T3/es active Active
- 2018-06-05 AU AU2018280741A patent/AU2018280741B2/en active Active
- 2018-06-05 HU HUE18731976A patent/HUE070907T2/hu unknown
- 2018-06-05 FI FIEP18731976.9T patent/FI3634419T3/fi active
- 2018-06-05 EP EP18731976.9A patent/EP3634419B1/en active Active
- 2018-06-05 MX MX2023013582A patent/MX2023013582A/es unknown
- 2018-06-05 CA CA3066188A patent/CA3066188A1/en active Pending
- 2018-06-05 WO PCT/EP2018/064767 patent/WO2018224497A1/en not_active Ceased
- 2018-06-05 CN CN201880050807.2A patent/CN110996957A/zh active Pending
- 2018-06-05 KR KR1020197038980A patent/KR102884301B1/ko active Active
- 2018-06-05 JP JP2019566909A patent/JP7292566B2/ja active Active
- 2018-06-05 DK DK18731976.9T patent/DK3634419T3/da active
- 2018-06-05 SG SG11201911599XA patent/SG11201911599XA/en unknown
- 2018-06-05 HR HRP20250390TT patent/HRP20250390T1/hr unknown
-
2023
- 2023-03-20 JP JP2023043718A patent/JP7485815B2/ja active Active
- 2023-09-11 US US18/244,773 patent/US20240000785A1/en active Pending
-
2024
- 2024-03-14 AU AU2024201694A patent/AU2024201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634419A1 (en) | 2020-04-15 |
| FI3634419T3 (fi) | 2025-05-02 |
| EP4509173A2 (en) | 2025-02-19 |
| HUE070907T2 (hu) | 2025-07-28 |
| AU2018280741B2 (en) | 2023-12-21 |
| HRP20250390T1 (hr) | 2025-05-23 |
| ES3018358T3 (es) | 2025-05-16 |
| CA3066188A1 (en) | 2018-12-13 |
| KR20200024797A (ko) | 2020-03-09 |
| AU2024201694A1 (en) | 2024-04-04 |
| JP7292566B2 (ja) | 2023-06-19 |
| US11759464B2 (en) | 2023-09-19 |
| PL3634419T3 (pl) | 2025-06-09 |
| EP3634419B1 (en) | 2025-01-29 |
| KR102884301B1 (ko) | 2025-11-11 |
| DK3634419T3 (da) | 2025-03-31 |
| CN110996957A (zh) | 2020-04-10 |
| EA201992812A1 (ru) | 2020-05-21 |
| MX2023013582A (es) | 2024-04-16 |
| JP2020522525A (ja) | 2020-07-30 |
| JP2023078315A (ja) | 2023-06-06 |
| AU2018280741A1 (en) | 2020-01-30 |
| JP7485815B2 (ja) | 2024-05-16 |
| SG11201911599XA (en) | 2020-01-30 |
| US20240000785A1 (en) | 2024-01-04 |
| EP4509173A3 (en) | 2025-06-04 |
| PT3634419T (pt) | 2025-04-04 |
| US20200179390A1 (en) | 2020-06-11 |
| WO2018224497A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014482A (es) | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. | |
| WO2020094698A3 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| NO20056251L (no) | Pyrimidin-2,4-dionderivater som gonadotropin-frigjorende hormon reseptor antagonist | |
| PH12021551196A1 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
| MX2021007184A (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan. | |
| MY195002A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12017500479B1 (en) | Liquid inhalation formulation comprising rpl554 | |
| TN2016000458A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer. | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| MX374955B (es) | Formulación de implantes de risperidona o paliperidona. | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| MX2019014483A (es) | Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis. | |
| ZA202304064B (en) | Quinoline cgas antagonist compounds | |
| PH12019501016A1 (en) | Treatment of cns diseases with sgc stimulators | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| EA201390618A1 (ru) | Режимы дозирования при лечении офтальмологического сосудистого заболевания | |
| WO2021023877A3 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| MX2020005921A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| WO2020089190A3 (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| RU2016124538A (ru) | Антагонисты гастрина для лечения и профилактики остеопороза | |
| JP2016538295A5 (enExample) | ||
| TN2017000248A1 (en) | Cgrp antagonist peptides |